

2017
ALSAC/ST. JUDE
ANNUAL REPORT






TABLE OF CONTENTS

A Great Children's Hospital

The Leading
Research Institution

America's Largest Healthcare Charity

A Vision of the Future

28
Leadership and Service

36
Financials

St. Jude Children's Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases.

As a cutting-edge research institution, world-class children's hospital and America's largest healthcare charity, we are dedicated to one goal:

Finding cures. Saving children.®

The mission of St. Jude Children's Research Hospital is to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. Consistent with the vision of our founder, Danny Thomas, no child is denied treatment based on race, religion or a family's ability to pay.

ALSAC – American Lebanese Syrian Associated
Charities – is the fundraising and awareness
organization for St. Jude. ALSAC is dedicated solely
to raising funds and awareness necessary to operate
and maintain St. Jude, now, and for the future.





"Thanks to St. Jude, our son has a second chance at life." Dear Friends of St. Jude,

Our son Christian is a sweet boy who is always looking for ways to help around the house. Whenever his little sister makes a mess, he is the first one with a broom in hand, ready to help clean. Earlier this year, we noticed Christian wasn't acting like himself. He had trouble using his right arm and was using his left hand for things he normally did with his right.

After repeated trips to the doctor, we received the devastating news that Christian suffered from a rare type of brain cancer called atypical teratoid rhabdoid tumor (ATRT). It was the hardest day of our lives.

Fortunately, we were referred to St. Jude Children's Research Hospital®, where Christian's treatment includes proton therapy and chemotherapy. Thanks to St. Jude, our son has a second chance at life.

At St. Jude, not only is Christian receiving exceptional care, but our entire family is also taken care of. If we were anywhere else, it would have been a much more stressful time. Here, we get to focus on Christian's care and not have to worry about anything else. St. Jude is unbelievable.

Thank you for supporting St. Jude,

Christina and Francisco,
Parents of St. Jude patient Christian

A GREAT CHILDREN'S HOSPITAL

Each year, about 8,500 kids pass through the doors of St. Jude Children's Research Hospital. They come to St. Jude from all 50 states and from around the world because St. Jude is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases.

But being diagnosed with cancer and going to a hospital, many times in a distant city, can be stressful for a child and their family. At St. Jude, we focus on the whole child – their physical and emotional health – as well as the well-being of siblings and the family unit. In fact, St. Jude is often where doctors send their toughest cases, because St. Jude has the world's best survival rates for some of the most aggressive forms of childhood cancer.

For many of our patients, St. Jude may be their first exposure to needles, medicine and diagnostic equipment, and it can be an intimidating and frightening time. That's why our compassionate caregivers help children cope with the challenges of hospitalization and treatment by providing age-appropriate explanations and activities to better prepare them for what's happening. These interactions also build trust so that patients and families know what to expect during this time of change.

As the number of childhood cancer survivors increases, we must consider quality of life not only during treatment but also after treatment ends. A full, rich life is what our patients deserve, and it's what we strive to give them from the moment they walk through the doors and become part of our St. Jude family.

Treatments invented at St. Jude have helped push the overall childhood cancer survival rate

from 20% to more than 80%

since we opened more than 50 years ago. We won't stop until no child dies from cancer.







St. Jude
has the largest
long-term follow-up clinic
for patients



In early 2016, hip pain kept Abi from her favorite activities – volleyball and tee ball.

Her mom, Jamie, thought it was growing pains until Abi started having headaches every day. In October, a bone scan and biopsy revealedAli was suffering from Ewing sarcoma, a type of bone cancer, with tumors in her pelvis, femur, shoulders and skull. A tumor on her lumbar spine fractured a vertebra, leaving her unable to walk.

Abi was immediately referred to St. Jude where treatment included 14 rounds of chemotherapy and 35 rounds of proton therapy. The tumors began to shrink and soon Abi was walking again.

She recently finished treatment and is thriving. On a recent family lake vacation, she jumped from the banks into the water – something her mom wasn't sure Abi would ever be able to do again.

THE LEADING RESEARCH INSTITUTION

When St. Jude Children's Research Hospital opened in 1962, a diagnosis of acute lymphoblastic leukemia (ALL), the most common childhood cancer, was all but a death sentence.

Today, through the support of donors and the work of some of the best scientific and medical minds anywhere, kids who come to St. Jude with ALL have a 94 percent chance of survival, the highest anywhere.

Those survival rates are being pushed ever higher thanks to cutting-edge technologies such as the St. Jude Red Frog Events Proton Therapy Center and the St. Jude—Washington University Pediatric Cancer Genome Project, the world's most ambitious effort yet to discover the origins of childhood cancers and seek new cures.

A new research center is part of a multi-billion dollar expansion, and we are increasing the number of patients being treated on St. Jude-led clinic trials.

What's more, St. Jude freely shares its groundbreaking discoveries. With the launch of St. Jude Cloud collaborative platform, knowledge and data can be shared more easily and quickly to advance research that could lead to helping even more children around the world suffering from cancer and other life-threatening diseases.



ST. JUDE RESEARCH HIGHLIGHTS

Evidence suggests migratory birds are not a reservoir for highly pathogenic flu viruses

Research led by St. Jude indicates that highly infectious influenza viruses do not persist in wild ducks and other aquatic birds – a finding that offers guidance about how best to combat flu outbreaks on poultry farms.

July 2016 | Proceedings of the National Academy of Sciences

CRISPR gene editing reveals new therapeutic approach for blood disorders

A report by an international team of scientists led by St. Jude offers hope that a unique gene editing technique could help overcome certain blood disorders such as sickle cell disease and beta-thalassemia, which can cause lifelong health problems.

August 2016 | Nature Medicine

Newly discovered immune cell type protects against lung infections during chemotherapy

A study from St. Jude identifies a new form of an immune cell that provided protection from bacterial pneumonia under conditions that mimicked cancer chemotherapy. The finding points to new ways of strengthening the immune system and protecting cancer patients during chemotherapy.

September 2016 | Proceedings of the National Academy of Sciences

Researchers reveal genomic landscape of core-binding factor acute myeloid leukemia

Scientists in the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project completed a detailed map of the genome of a common form of acute myeloid leukemia in children that makes up about 30 percent of pediatric AML cases.

October 2016 | Nature Genetics

Potential targeted therapy found for newly identified leukemia subtype with poor outcome

An international team led by St. Jude identified new details about a high-risk subtype of acute lymphoblastic leukemia (ALL) and identified a drug that shows promise for treating the disease, which is linked to lower survival rates.

November 2016 | Nature Communications

Infant's prolonged infection reveals mutation that helps bacteria tolerate antibiotics

A life-threatening bacterial infection in an infant fighting leukemia at St. Jude led to an important discovery about antibiotic resistance in this dangerous infection. By sequencing the bacteria's DNA, researchers linked a single mutation in the bacteria to its ability to survive against antibiotics that effective.

January 2017 | mBio

Research leads to new treatment recommendations for a high-risk pediatric leukemia

In an international study led by St. Jude, researchers identified three genetic missteps that drive acute megakaryoblastic leukemia (AMKL) in children without Down syndrome. The findings have prompted researchers to revise their recommendations for screening and treatment of AMKL.

January 2017 | Nature Genetics

Success of sensory cell regeneration raises hope for hearing restoration

One side effect for some childhood cancer patients is hearing loss due to certain chemotherapy agents that can damage auditory hair cells. St. Jude researchers discovered a way to regenerate auditory hair cells in a laboratory setting. By manipulating genes, researchers induced cells to take on the appearance of immature hair cells and begin producing some of their signature proteins.

April 2017 | Cell Reports





New insights into retinoblastoma revealed in map of cell's genetic controls

New research from the St. Jude Children's Research Hospital—Washington University Pediatric Genome Project has mapped the intricate changes that occur in the organization of the cell nucleus to determine how cells in the retina of the eye transition from immature to more complex cells, and the timeframe in which some of these cells become cancerous.

May 2017 | Neuron

Discovery of a critical switch in cell development could lead to treatments for cancer

Researchers at St. Jude discovered a switch in the machinery of cells that could open new doors to research and possible treatment of medulloblastoma, the most common malignant brain tumor in children. The research could lead to more precise targeted drug treatments.

June 2017 | Cell Reports

Researchers chart pathway to 'rejuvenating' immune cells to fight cancers

St. Jude researchers have identified a mechanism in specialized white blood cells that could explain limited success with a promising immunotherapy. The finding offers a potential new approach for developing more powerful and durable immunotherapies to fight childhood cancer, as well as treatments for viruses such as HIV.

June 2017 | Cell

ST. JUDE FREELY SHARES THE DISCOVERIES WE MAKE

and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children.

Pepe is a typical 2-year-old, happy and bubbly and always on the move.

However, in October 2015, he developed a cough that wouldn't go away. His mother, Tiffany, took him to the emergency room, where he was diagnosed with pneumonia.

Unfortunately, the cough returned and Pepe started having difficulty breathing. A CT scan revealed a mass and Pepe was immediately referred to St. Jude, where he was found to suffer from a cancer called neuroblastoma.

His treatment included chemotherapy and a bone marrow transplant. Today, Pepe is a happy boy who loves to play with his older brother and sister. "Even during treatment, he always has a smile on his face," said Tiffany. "He's made us stronger."



More than 500 of the costs of St. Jude are

covered by generous donors





1,000,000 One million volunteers support St. Jude

LOVE Finding cures. Saving children.

St. Jude has million active donors



Each year

31,000

activities help raise funds and awareness for St. Jude

AMERICA'S LARGEST HEALTHCARE CHARITY

Every year, millions of generous supporters and volunteers embrace our mission to find cures for children fighting cancer and other lifethreatening diseases. They do so through generous donations, small and large, more than 31,000 events each year, including fitness events such as marathons, cycling and walk/run events, as well as with workplace giving, dinner galas and golf tournaments.

That support means the dedicated scientists and doctors at St. Jude have the resources they need to conduct pioneering research to help save children's lives. It also means a great deal of trust has been shown St. Jude by our supporters and peer organizations who consider us the "highest ranked health non-profit brand" (Harris Poll Equitrend®) and the "number one most inspirational brand" (World Value Index).

That recognition translates into global awareness and ultimately helps ensure that no family will ever receive a bill from St. Jude for treatment, travel, housing or food – because all a family should worry about is helping their child live.

This commitment makes such a critical difference in the lives of the children and families of St. Jude. It means that we can dare to dream as big as St. Jude founder Danny Thomas, who believed we would reach a day when no child dies in the dawn of life.

Mikayla is an artistic girl who loves theater, drawing and singing in the choir.

But, in late 2016, Mikayla was in and out of the doctor's office in January, and no one could pinpoint just what was wrong. Then, her health worsened and her parents, Kathy and Michael, rushed her to the emergency room where tests revealed Mikayla had a cancerous brain tumor called a medulloblastoma.

After surgery to remove the tumor, Mikayla was referred to St. Jude. Treatment included four rounds of chemotherapy and 30 rounds of proton therapy. Now in fifth grade, Mikayla is a travel buff who loves to read and play games on her tablet.

"St. Jude means everything to us," Kathy said. "They saved our daughter's life. The support we had was so comforting."





A VISION OF THE FUTURE: ST. JUDE GLOBAL

Experts estimate that up to 300,000 children are diagnosed with cancer worldwide each year. The majority of these children live in low-and middle-income countries, where they lack access to adequate diagnosis and treatment. In fact, in many of these countries, it is still 1962, the year Danny Thomas opened the doors of St. Jude and a time when just one in five cancer patients survived into adulthood.

To turn this tide, St. Jude Global is expanding the reach of the world-class treatment and research already available at St. Jude by creating a network of interactive programs and institutions, and forming a global alliance that will improve access to care, enhance the quality of care children receive and provide better options for cures.

Through its focus on three core areas – education, capacity building and research – St. Jude Global aims to grow the number of children whose care it influences from 3 to 30 percent within the next decade. The long-term goal is for all children with cancer to have access to quality care – no matter where they live – so that no child should die in the dawn of life.

Like kids everywhere, David enjoys video games and playing piano and guitar.

Growing up as an American boy in Honduras, he has taken full advantage of his unique experience and learned to speak three languages – English, Spanish and a local dialect of the island where he and his family live.

When David began feeling ill, doctors discovered he had a strain of acute lymphoblastic leukemia called Gamma Delta t-cell ALL. In Honduras, his grandfather, Tom, had to fight through crowds to have David seen by a doctor. Conditions were unsanitary, there was no food and Tom had to sleep on the concrete floor beneath David's bed for the two nights they were there.

They were referred to St. Jude and, upon arriving, Tom said, "An enormous burden was released." St. Jude is seeking to unburden families the world over through St. Jude Global, connecting networks of healthcare providers and foundations to improve care for all.

Because it is such a rare strain of ALL, David's treatment will be more extensive and he'll undergo nearly three years of chemotherapy. David's family is extremely grateful for the care he has received at St. Jude. "This is a truly special place," Tom said. "It is a drop right down from heaven."





ALSAC/ST. JUDE BOARD OF DIRECTORS AND GOVERNORS

The members of the ALSAC/St. Jude Boards of Directors and Governors are volunteers who serve without compensation. They come from across the country to support the lifesaving work of St. Jude, and many represent the second and third generations of their families to serve on the Boards. An honorary body of emeritus members recognizes the distinguished service on the Boards by those unable to continue to actively participate.

FY17 ALSAC Board of Directors

Officers

Paul J. Ayoub

Partner, Nutter McClennen & Fish LLP Chair

James B. Barkate

President, Southern Abstracts Inc. Vice Chair

Frederick R. Harris

Retired Secretary

FY17 St. Jude Board of Governors

Officers

Martha Perine Beard

Retired Chair

Camille F. Sarrouf Jr.
Partner, Sarrouf Law LLP

Vice Chair

Susan Mack Aguillard, MD

Pediatrics East Secretary

FY17 Members

Joyce A. Aboussie

Owner and CEO, Aboussie & Associates

Mahir R. Awdeh, MD

Cardiologist, Cardiology Associates of Memphis

Joseph S. Ayoub Jr.

President, Varuna Strategies LLC

Frederick M. Azar, MD

Chief of Staff, Campbell Clinic

Sheryl A. Bourisk

Partner, BoMin Creative Productions

Robert A. Breit, MD

Radiologist, Smart Scan MRI

Terry L. Burman

Retired

Ann M. Danner

Retired

Joseph M. DeVivo

CEO, InTouch Health

Fred P. Gattas III, PharmD

Nuclear Pharmacist, Triad Isotopes Inc.

Ruth C. Gaviria

Chief Marketing Officer, Entercom Communications

Christopher B. George, MD

Hematologist/Oncologist, Florida Cancer Specialists

Judy A. Habib

President and CEO, KHJ Brand Activation

Gabriel G. Haddad, MD

Physician-in-Chief,

Rady Children's Hospital

Paul K. Hajar

Retired

Charles C. Hajjar

Owner, Hajjar Management Co. Inc.

Fouad M. Hajjar, MD

Hematologist/Oncologist, Children's Center for Cancer and

Blood Diseases

Frederick R. Harris Jr., MD

Gastro One

Bruce B. Hopkins

Chair, West Tennessee Region, First Tennessee Bank

J. David Karam

CEO, Sbarro Inc.

Michael D. McCov

Sheriff, Peoria County, Illinois

Robert T. Molinet

Global Chief Compliance and Governance Officer, FedEx Corporation

James O. Naifeh Jr.

Team Member, Bernard Health

Ramzi N. Nuwayhid

Private Wealth Advisor, Merrill Lynch Private Banking and Investment Group

Thomas J. Penn, III

President and Owner, Los Angeles

Football Club

Joseph C. Shaker

President, Shaker Recruitment Advertising and Communications Inc.

Joseph G. Shaker

Chairman of the Board, Shaker Recruitment Advertising and Communications Inc.

George A. Simon II

Retired

Michael C. Simon

Managing Principal, Traverse Pointe Partners

Paul J. Simon

President, U.S. Group Inc.

Tony Thomas

Partner, Witt/Thomas Productions

Richard M. Unes

Senior Project Manager, Peoria Metro Construction

Paul H. Wein

Partner, LaFave Wein and

Frament PLLC

Thomas C. Wertz

Senior Vice President of Wealth Management, UBS Financial Services

Tama H. Zaydon

Executive Director of Investments, Oppenheimer & Company

FY17 Emeritus Members

(Non-voting members of the Boards)

Thomas G. Abraham

Chairman of the Board,

Anthony R. Abraham Foundation

Jack A. Belz

Chairman and Chief Executive Officer,

Belz Enterprises

Stephen J. Camer, MD

General Surgeon,

New England Baptist Hospital

V. Reo Campian

Retired

Joseph G. Cory, PhD

Retired

Leslie S. Dale

Retired

Lewis R. Donelson III

Retired

Edward M. Eissey, PhD

Retired

George Elias Jr.

Attorney, Law Offices

of George Elias Jr.

Hasan M. Elkhatib

Retired

Fred P. Gattas Jr.

President, Gattas Company

Sam F. Hamra

Chairman, Hamra Enterprises

Theodore J. Hazer

Retired

Richard J. Karam

Attorney, Law Offices

of Richard J. Karam

James A. Kinney

Retired

Salli E. LeVan

Retired

Donald G. Mack, MD

Retired

George M. Maloof

Retired

Paul J. Marcus

President, Marcus Capital

Management Inc.

James O. Naifeh

Retired

David B. Nimer

Independent Import and Export Professional

Talat M. Othman

President, Grove Financial Inc.

Manal B. Saab

CEO, Sorrensen Gross Construction Services

Camille F. Sarrouf Sr.

Partner, Sarrouf Law LLP

Frederick W. Smith

Chairman, President and CEO,

FedEx Corporation

Ronald A. Terry

Retired

Terre Thomas

Writer

Pat Kerr Tigrett

President and CEO, Pat Kerr Inc.

Robert P. Younes, MD

Physician, Conmed Healthcare

Management Inc.

Ramzi T. Younis, MD

Physician, Bascom Palmer

Eye Institute

Ex Officio Voting Members

James R. Downing, MD

President and CEO, St. Jude

Children's Research Hospital

Richard C. Shadyac Jr.

President and CEO. ALSAC

Chief Governance Officer Corporate Secretary

Leah Domitrovic

Epsilon Sigma Alpha Representative

Sherry Day

(Non-elected member)

St. Jude National Outreach Director

Marlo Thomas

SCIENTIFIC ADVISORY BOARD

The Scientific Advisory Board is an autonomous panel of renowned physicians and scientists who help foster the medical and scientific development of St. Jude, providing guidance and insight on research directions, clinical activities and institutional policy.

FY17 Chair

Mignon L. Loh, MD
UCSF Benioff Chair of
Children's Health
Deborah and Arthur Ablin Endowed
Chair in Pediatric Molecular Oncology
Professor and Division Chief,
Hematology/Oncology
University of California Benioff
Children's Hospital

FY17 Vice Chair

Theodore S. Lawrence, MD, PhD, FASTRO, FASCO

Isadore Lampe Professor and Chair Department of Radiation Oncology University of Michigan Medical School

FY17 Members

Daphne A. Haas-Kogan, MD Professor, Radiation Oncology Harvard Medical School Chair, Department of Radiation Oncology Dana-Farber Cancer Institute

Benjamin F. Cravatt III, PhD Professor and Chair, Department of Chemical Physiology The Skaggs Institute for Chemical Biology The Scripps Research Institute

John Kuriyan, PhD
Investigator, Howard Hughes
Medical Institute
Chancellor's Professor
Professor of Molecular Biology
and Chemistry
University of California at Berkeley

Patricia A Ganz, MD

Distinguished Professor Health Policy and Management and Medicine UCLA Fielding School of Public Health UCLA David Geffen School of Medicine Director, Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center University of California at Los Angeles

Michael K. Rosen, PhD

Investigator, Howard Hughes Medical Institute Mar Nell and F. Andrew Bell Distinguished Chair in Biochemistry University of Texas Southwestern Medical Center

David P. Harrington, PhD

Professor, Biostatistics Harvard T.H. Chan School of Public Health Professor, Biostatistics and Computational Biology Dana-Farber Cancer Institute

Ellis J. Neufeld MD, PhD

Egan Family Foundation Professor in Transitional Medicine,
Harvard Medical School
Medical Director,
Boston Hemophilia Center
Dana-Farber/Boston Children's
Cancer and Blood Disorders Center
Associate Chief, Division of
Hematology/Oncology
Boston Children's Hospital

Jennifer A. Pietenpol, PhD

Benjamin F. Byrd Jr. Endowed Chair in Oncology Director, Vanderbilt-Ingram Cancer Center Professor, Biochemistry, Cancer Biology and Otolaryngology Vanderbilt University School of Medicine Executive Vice President, Research,

Vanderbilt University Medical Center

Raphael E. Pollock, MD, PhD, FACS

Professor and Director, Division of Surgical Oncology Vice Chairman for Clinical Affairs, Department of Surgery Surgeon-in-Chief, James Comprehensive Cancer Center Surgeon-in-Chief, The Ohio State University Health System

Aviv Regev, PhD

Professor, Department of Biology Massachusetts Institute of Technology Core Member and Chair of the Faculty Director, Cell Circuits Program and Klarman Cell Observatory Broad Institute Investigator, Howard Hughes Medical Institute

David H. Rowitch, MD. PhD

Professor and Head of Paediatrics Wellcome Trust Senior Investigator Wellcome Trust-MRC Cambridge Stem Cell Institute Department of Paediatrics University of Cambridge

Michel W. Sadelain, MD, PhD

Stephen and Barbara Friedman Chair Director, Center for Cell Engineering Memorial Sloan-Kettering Cancer Center

Joseph W. St. Geme III, MD

Leonard and Madlyn Abramson Professor of Pediatrics and Microbiology Perelman School of Medicine, University of Pennsylvania Physician-in-Chief and Chair, Department of Pediatrics The Children's Hospital of Philadelphia

Akiko Shimamura, MD, PhD

Associate Professor of Pediatrics Harvard Medical School Director, Bone Marrow Failure and Myelodysplastic Syndrome Programs Dana-Farber Cancer Institute Boston Children's Hospital

FUNDRAISING AND AWARENESS GUIDANCE

The talented and dedicated volunteers who serve on the Professional Advisory Board and the ALSAC Leadership Board are leaders and experts in their fields. They meet regularly to provide guidance to ALSAC on strategic fundraising issues and ways to raise awareness for the St. Jude mission: *Finding cures. Saving children.**

FY17 Professional Advisory Board

Jose Barra

Executive Vice President Optum Eden Prairie, MN

Marty Belz

Chairman Peabody Hotel Group Memphis, TN

Scott Bowman

Chief Executive Officer Global Net Lease New York, NY

Douglas (Doug) H. Brooks

CEO and Chairman (Retired)
Brinker International
Plano. TX

Jeb Bush, Jr.

Chief Operating Officer Jeb Bush and Associates, LLC Coral Gables, FL

Kay Dempsey

President and Chief Executive Officer The Dempsey Companies Atlanta, GA

Christine Duffy

President Carnival Cruise Line Miami, FL

Michael Francis

Founder & CEO Farview Associates, LLC Orono, MN

Don Germano

Senior Vice President, Operations DICK'S Sporting Goods Coraopolis, PA

Rich Hagen

President, TradeKing Securities, LLC CEO, TradeKing Advisors, Inc. Charlotte, NC

Mike Hamra

CEO & President Hamra Enterprises Springfield, MO

Robert Hureau

Executive Vice President, Chief Financial Officer Pharmaceutical Product Development, Inc. Wilmington, NC

Kelle Ilitch

Co-owner Pure Ride Birmingham, MI

Alasdair B. James

President & CEO Pier 1 Imports Fort Worth, TX

George Joulwan

General (Retired - U.S. Army) Arlington, VA

Kumud Kalia

Senior Vice President, Chief Information Officer Akamai Technologies Santa Clara, CA

Jim Karam

Entrepreneur Columbus, OH

Mary Vaughan Lester

Philanthropist California, TX

Anthony (Tony) P. Lewis

Chairman and CEO EOR Energy Services, LLC Houston, TX

Michael J. Lynch

Senior Relationship Manager Managing Director Bank of America Merrill Lynch New York, NY

Maguy Maccario-Doyle

Ambassador Embassy of the Principality of Monaco Washington DC

T. Allan McArtor

Chairman and CEO Airbus Group, Inc. Herndon, VA

Johnny B. Moore, Jr.

Regional President and CEO SunTrust Bank Memphis, TN

Marianne Silver

Chief People Officer, Founder Coyote Logistics, LLC Chicago, IL

Gary Tobey

Chairman and CEO Haworth Marketing and Media Los Angeles, CA

Mark Tritton

Executive Vice President and Chief Marketing Officer Target Minneapolis, MN

Eric Trump

Executive Vice President Trump Organization New York, NY

LuAnn Via

Board Director, Advisor Strata Sciences, Inc. University of Miami, FL

Russell Weiner

President Domino's USA Ann Arbor, MI Dr. Phil Wenk

President and CEO Delta Dental of Tennessee Nashville, TN

Duncan Williams

President and CEO Duncan-Williams, Inc. Memphis, TN

Craig Witsoe

CEO

Elo Touchscreen Solutions Milpitas, CA

FY17 ALSAC Leadership Board

Marilyn Aboussie

Chief Justice (Retired) San Angelo, TX

Amin J. Barakat

Physician

Clinical Professor of Pediatrics Georgetown University Medical

Washington, DC

Joseph G. (Joe) Bisceglia

Partner

Jenner & Block LLP Chicago, IL

Pamela Silva Conde

Journalist/Co-Anchor Univision Network Miami, FL

Nick Caporella

Chairman and CEO National Beverage Corp. Ft. Lauderdale. FL

Terri Carr

Wisteria Fashions Potomac, MD

Robert (Bob) Corliss

CEO, Robert Talbott, Inc. Founding Partner, CorlissMoore Monterey, CA

Chaz Corzine

The MWS Group Nashville, TN

Joseph K. DeLapp II

President and CEO Visioneering Technologies, Inc. Roswell, GA

Stuart Elias

American Airlines Manager **DFW Customer Operations**

Administration

DFW Hub Administration

Flower Mound, TX

Charles A. Feghali

President NGE Systems, LLC McLean, VA

Andrew Graves

Vice President JPMorgan Chase Bank, N.A. J.P. Morgan Securities, LLC New York, NY

Marilena Greig

Philanthropist and Volunteer New Canaan, CT

Trish Coury Gustafson

Realtor

Coldwell Banker Previews International Newport Beach, CA

Eileen Hutton

Retired Co-owner, Brilliance Audio Hilton Head, SC

Linda Johansen-James

CEO & President

International Retail Management and Consulting Group, LLC Las Vegas, NV

Lawrence K. Jensen

President and CEO Commercial Advisors, LLC Memphis, TN

Albert F. Johary, M.D.

Physician Dunwoody, GA

Rochelle Joseph

Owner

Image Consulting and Marketing Newburyport, MA

Margo R. Keyes

Vice Chairman Key Development, LLC Addison, TX

Wes Kraker

President and CEO Pathmark Transportation Memphis, TN

Eunice Mazloom

Philanthropist and Volunteer Arlington, VA

Scott Nietschmann

Area Director of Operations Southern Hospitality Ventures, Inc. Lincoln, NE

Kevin Pautler

Caterpillar, Inc. (Retired) The Villages, FL

William C. Perez

General Counsel Pay LLC New Orleans I A

Thomas M. Rashid, M.D.

St. Francis Hospital, Department of Urology Peoria, IL

Andrew San Marco

Managing Director Tradition New York, NY

Rick Semonis

Vice President of Employee Benefits J.L. Hubbard Insurance and Bonds Peoria, IL

Jack Soden

CEO

Elvis Presley Enterprises, Inc. Memphis, TN

Gary B. Stone

President and CEO Strategic Thinking One on One Houston, TX

John L. Strauss

President

The John and Bonnie Strauss Foundation Dallas, TX

John Tanner Vice Chair

Prime Policy Group Washington, DC

ST. JUDE EXECUTIVE COMMITTEE

James R. Downing, MD

President and Chief Executive Officer

Charles Roberts, MD, PhD

Cancer Center Director **Executive Vice President**

Mary Anna Quinn

Chief Administrative Officer **Executive Vice President**

James Morgan, PhD

Scientific Director

Executive Vice President

Ellis Neufeld, MD, PhD

Clinical Director

Executive Vice President

Carlos Rodriguez-Galindo, MD

Chair, Global Pediatric Medicine **Executive Vice President**

Robyn Diaz, JD

Chief Legal Officer

Senior Vice President

Terrence Geiger, MD, PhD

Deputy Director for Academic and Biomedical Operations Senior Vice President

Chief Financial Officer Senior Vice President

Keith Perry

Chief Information Officer Senior Vice President

Shari Capers

Vice President, Strategic Planning and Decision Support

Andrew Davidoff, MD

Chair, Surgery

Michael Dyer, PhD

Chair, Developmental Neurobiology

David Ellison, MD, PhD

Chair, Pathology

Amar Gajjar, MD

Chair. Pediatric Medicine

Doug Green PhD

Chair, Immunology

Gerard Grosveld, PhD

Chair, Genetics

Richard Lee, PhD

Interim Chair, Chemical Biology

and Therapeutics

Thomas Merchant, DO, PhD

Chair, Radiation Oncology

Zoltan Patay, MD, PhD

Interim Chair, Diagnostic Imaging

Sean Phipps, PhD

Chair, Psychology

Ching-Hon Pui, MD

Chair, Oncology

Mary Relling, PharmD

Chair, Pharmaceutical Sciences

Les Robison, PhD

Chair, Epidemiology

Charles Sherr, MD, PhD

Chair, Tumor Cell Biology

Kumar Srivastava, PhD

Interim Chair, Biostatistics

J. Paul Taylor, MD, PhD

Chair, Cell and Molecular Biology

Elaine Tuomanen, MD

Chair, Infectious Diseases

Mitch Weiss, MD, PhD

Chair, Hematology

Babis Kalodimos, PhD

Chair, Structural Biology

Jinghui Zhang, PhD

Chair, Computational Biology

Stephen Gottschalk, MD

Chair, Bone Marrow Transplant

and Cellular Therapy

Suzanne Baker, PhD

Co-leader, Neurobiology and

Brain Tumor Program

Melissa Hudson, MD

Director, Cancer Survivorship Division

Co-Leader, Cancer Prevention and

Control Program

Alberto Pappo, MD

Director, Solid Tumor Division Co-Leader, Developmental Biology

and Solid Tumor Program

Charles Mullighan, MBBS, MD Member, Pathology

Martine Roussel, PhD

Member, Tumor Cell Biology

Victor Santana, MD

Member, Oncology

Jon McCullers, MD, PhD

Chair, Pediatrics at the University of Tennessee Health Science

Center (UTHSC)

Pediatrician-in-chief for Le Bonheur

Children's Hospital

ALSAC LEADERSHIP TEAM

Executive Leadership

Richard C. Shadyac Jr.

President and Chief Executive Officer

Emily Callahan

Chief Marketing Officer

Emily S. Greer

Chief Administrative Officer

Sara Hall

Chief Legal Officer

Martin Hand

Chief Donor Officer

Melanee Hannock

Chief Digital and Innovation Officer

Sue Harpole

Chief Development Officer

Robert Machen

Chief Information Officer

Anurag Pandit

Chief Investment Officer

Jeffrey T. Pearson

Chief Financial Officer

George P. Shadroui

Chief Strategy Officer

Steve Froehlich

Deputy Chief Development Officer

Senior Vice Presidents

Chris Boysen

Field Operations

Wilfred Busby

Enterprise Contact Center

Steve Cox

Marketing and Communications

Steele Ford

Strategic Partnerships

Aimee Hall

Digital

Diane Heyman

Human Resources

David Jacques

Information Technology

Betty MacDougall

CEO Operations

Reginald Porter

Enterprise Operations

Mike Siegel

Marketing

Regina Watson

Gift Planning

Vice Presidents

Brenda Abshure

ALSAC Liaison Office and Operations

Amy Lahey

Administrative Operations and

Information Security

Evelyn Homs

Multicultural Marketing and Business Development

Kim Humphries

Global Alliances

Lauri Prather

Legal

Kelly Schulz

CEO Operations

Kevin Snyder


Communications



COMBINED FINANCIAL HIGHLIGHTS FOR FISCAL YEAR 2017

Years Ended June 30 (in thousands)

2017	2016
\$1,352,732	\$1,162,369
124,099	114,471
89,431	88,797
387,143	(2,292)
18,201	19,886
1,971,606	1,383,231
427,945	389,040
368,334	357,419
126,299	96,251
922,578	842,710
211,272	202,204
143,794	134,681
1,277,644	1,179,595
(114)	(963)
702,000	202,673
3,957,917	3,755,244
\$4,659,917	3,957,917
	\$1,352,732 124,099 89,431 387,143 18,201 1,971,606 427,945 368,334 126,299 922,578 211,272 143,794 1,277,644 (114) 702,000 3,957,917



"No child should die in the dawn of life."

That was the belief of our founder, Danny Thomas, and that is at the heart of our mission today. With your continued support, we will never stop looking for the cures that will save the lives of children with cancer and other life-threatening diseases. We will continue to share our research discoveries and provide the very best in patient care.

And families will never receive a bill from St. Jude for treatment, travel, housing or food—because all a family should worry about is helping their child live. Thank you for being a part of this lifesaving work.



To view the 2017 St. Jude Annual Report online, visit stjude.org/financials

Left: St. Jude patient Camila, blood cancer **On the cover:** St. Jude patient Javier, mixed germ cell tumor

